Abstracts tagged "tumor necrosis factor (TNF) and vasculitis"

Abstract Number: 1691 • 2019 ACR/ARP Annual Meeting
Efficacy of TNF α Inhibitors for Refractory Vascular Behcet’s Disease: A Multicenter Observational Study of 27 Patients
Aysun Aksoy ¹, Ayten Yazici ², Ahmet Omma ³, Ayşe Cefle ⁴, Fatos Onen ⁵, Unal Tasdemir ⁶, Tulin Ergun ⁷, Haner Direskeneli ⁸ and Fatma Alibaz-Oner⁹, ¹Marmara University Faculty of Medicine, Division of Internal Medicine, Department of Rheumatology, Istanbul, Turkey; University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom, Istanbul, Istanbul, Turkey, ²Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, ³Health Sciences University, Ankara Numune Training and Research Hospital, Department of Rheumatology, Ankara, Turkey, ⁴Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ⁵Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ⁶Dokuz Eylul University, School of Medicine Division of Internal Medicine Rheumatology Department, izmir, Turkey, ⁷Marmara University School of Medicine Dermatology Department, istanbul, Turkey, ⁸Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, ⁹Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey
Background/Purpose: Vascular involvement is one of the major causes of morbidity and mortality in Behcet’s Disease (BD) patients. Immunosuppressive (IS) agents are the mainstay of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].